Avapritinib is approved for a rare subtype of GIST with a PDGFRA (D842V) mutation [11], but has failed to demonstrate superiority over regorafenib as third-line in unselected GIST patients [12]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.